Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company committed to merging traditional therapeutics with psychedelic research to address a variety of underserved conditions. The company's focus spans post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer's disease, Parkinson's disease, and other rare neurological disorders.
Silo's mission is to identify and license transformative assets, funding cutting-edge research to enhance patient well-being and advance the healthcare industry. Recent achievements include the filing of a provisional patent for SP-26, a ketamine-based implant for chronic pain management, and the exclusive licensing of SPC-15 from Columbia University, a novel intranasal treatment for PTSD and anxiety.
Core Business and Projects
- SPC-15: An intranasal treatment targeting PTSD and stress-induced anxiety disorders. Silo has exercised its option to license SPC-15 from Columbia University, with preclinical studies showing promising results.
- SP-26: A time-release, ketamine-loaded implant aimed at fibromyalgia and chronic pain relief. The implant has shown positive results in pre-clinical studies and is expected to be the first at-home approved ketamine-based therapeutic if it passes clinical trials.
- SPC-14: An intranasal compound for the treatment of Alzheimer's disease, showing potential in preclinical studies for improving cognitive function and stress reduction.
- SPU-16: A CNS-homing peptide targeting multiple sclerosis (MS), developed in collaboration with the University of Maryland, Baltimore.
Silo's innovative approach combines traditional therapies with psychedelic treatments, aiming to develop novel formulations and drug delivery systems. The company's robust pipeline and strategic partnerships with leading medical universities position Silo at the forefront of biopharmaceutical advancements.
Financial Condition and Partnerships
Silo Pharma collaborates extensively with Columbia University and the University of Maryland, Baltimore, providing essential financial resources to advance their research from the clinical stage to commercialization. The company is financially positioned to support ongoing and future projects that could significantly impact the medical and psychedelic treatment landscape.
For more information, visit www.silopharma.com and connect on social media at LinkedIn, X, and Facebook.
Silo Pharma announced its common stock will commence trading on Nasdaq under the symbol SILO on September 27, 2022. The company has priced an underwritten public offering of 1,000,000 shares at $5.00 per share, aiming to raise $5 million before expenses. Proceeds will fund product development, marketing, and working capital, with potential use for acquiring complementary businesses. The transaction is expected to close by September 29, 2022. Laidlaw & Company is the sole book-running manager for this offering.
Silo Pharma, Inc. (OTCQB: SILO) announced a 1-for-50 reverse stock split effective September 15, 2022. This action is part of the company's strategy to qualify for listing on The Nasdaq Capital Market. Following the reverse split, approximately 1,987,906 shares will be outstanding. The reverse stock split aims to help Silo Pharma meet the minimum share price requirement for Nasdaq. The temporary trading symbol will change to "SILOD" until the Nasdaq listing is finalized.
Silo Pharma, Inc. (OTCQB: SILO) announced positive results from an animal study demonstrating its topical Ketamine formulation's effectiveness in reducing neuropathic nerve pain. The study showed a significant reduction in both allodynia and hyperalgesia using its patented delivery system in partnership with Zylo Therapeutics. Notably, day seven and day nine evaluations showed no erythema or swelling, indicating a favorable safety profile, which is promising for upcoming toxicology studies. CEO Eric Weisblum emphasized the potential benefits for patients with Fibromyalgia and Rheumatoid Arthritis.
Silo Pharma, Inc. (OTCQB: SILO) announced positive results from animal studies demonstrating the effectiveness and reduced toxicity of its novel liposomes using a subcutaneous delivery method for anti-arthritic agents. CEO Eric Weisblum stated that this method is well-suited for targeted drug delivery, enhancing efficacy and minimizing systemic toxicity. Previous studies with intravenous injections showed promising results, and the new findings indicate that subcutaneous administration is comparable in performance, with potential for even greater effectiveness.
Silo Pharma (OTCQB: SILO) announced an expansion of its Commercial Evaluation License Agreement with the University of Maryland Baltimore for next-generation Liposomal Peptides aimed at treating autoimmune diseases. Positive results from pre-clinical tests in arthritis models were highlighted, showing significant therapeutic effects of specific peptides (NQR and RGD). The global market for autoimmune disease therapeutics is projected to exceed $150 billion by 2025, bolstering Silo's prospects for growth and investment potential.
Silo Pharma, Inc. (OTCQB: SILO) has successfully dosed patients with Parkinson's disease in a study in collaboration with the University of California San Francisco (UCSF). This research aims to examine the effects of psilocybin on inflammatory markers in these patients. The study is part of UCSF's Translational Psychedelic Research (TrPR) Program, which investigates the impact of psychedelics on brain health. CEO Eric Weisblum highlighted this milestone, expressing optimism about the forthcoming results and future patient cohorts.
Silo Pharma (OTCQB: SILO) announced the production of its first batch of liposomes for a preclinical study targeting anti-arthritic activity through its SPU-21 compound. This study will be conducted by Frontage Laboratories. The CEO, Eric Weisblum, emphasized that this development advances the research on SPU-21, which has potential applications in autoimmune diseases like rheumatoid arthritis (RA). The liposomes are designed to enhance drug delivery and effectiveness while reducing toxicity.
Silo Pharma, Inc. (OTCQB: SILO) has partnered with Frontage Laboratories to advance its Central Nervous System Peptide, SPU-16, and Joint Homing Peptide, SPU-21, technologies toward clinical application. This agreement aims to facilitate a Pharmacokinetic Study in animals, which will analyze doses and plasma samples. CEO Eric Weisblum highlighted the potential of these peptides to enhance therapeutic effects while reducing systemic toxicity, with applications in treating central nervous system and autoimmune diseases.
Silo Pharma, a developmental stage biopharmaceutical company, announced its partnership with IBN to enhance corporate communications. This collaboration aims to leverage IBN's extensive investor distribution network to raise awareness for Silo's innovative therapeutic solutions targeting PTSD, Alzheimer’s, and other neurological disorders. Silo has established research agreements with leading universities, including studies on ketamine and psilocybin for Parkinson’s disease and inflammation. This partnership underscores Silo's commitment to advancing medical research and developing transformative treatments.
Silo Pharma (OTC QB: SILO) announced the extension of its exclusive option agreement with the University of Maryland to explore joint-homing peptides for treating rheumatoid arthritis and other autoimmune diseases. This technology aims to enhance therapeutic delivery to diseased joints, improving treatment efficacy while minimizing systemic toxicity. CEO Eric Weisblum highlighted the potential of these peptides as a revolutionary drug delivery platform, emphasizing the need for innovative therapeutics for rare diseases.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
What does Silo Pharma, Inc. specialize in?
What are Silo Pharma's leading development programs?
Who are Silo Pharma's research partners?
What recent achievements has Silo Pharma announced?
How does Silo Pharma aim to impact the healthcare industry?
Where can I find more information about Silo Pharma?
What is the significance of Silo Pharma's SP-26 program?
What progress has been made with the SPC-15 program?
What conditions does Silo Pharma aim to address with its treatments?
How does Silo Pharma fund its research projects?
